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Abstract
Background: Non-alcoholic steatohepatitis (NASH) is a chronic liver disease that is capable of  progressing to end-stage 
liver disease, but generally has a benign course. Non-alcoholic steatohepatitis (NASH) is a growing public health problem 
with no approved therapy. NASH projected to be the leading cause of  liver transplantation in the United States by 2020. 
Obesity, non-insulin-dependent diabetes mellitus and hyperlipidaemia are the most common associations of  the disease. 
Global prevalence of  NASH is 10-24% amongst general population but increases to 25–75% in obese diabetic individuals. 
Objective: There is an urgent need for efficient therapeutic options as there is still no approved medication. The aim of  this 
study was to detect changes in biochemical parameters including insulin resistance, cytokines, blood lipid profile and liver 
enzymes following weight loss in patients with non-alcoholic steatohepatitis. 
Materials and methods: One hundred obese patients with NASH, their age between 35-50 years, body mass index (BMI) 
from 30 to 35 Kg/m2 were included in the study in two subgroups; the first group (A) received moderate aerobic exercise 
training in addition to diet regimen , where the second group (B) received no treatment intervention. 
Results: The mean values of  leptin, TNF-α, IL6, IL8, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), 
Homeostasis Model Assessment-Insulin Resistance- index (HOMA-IR), Total Cholesterol (TC), Low Density Lipoprotein 
Cholesterol (LDL-c) , Triglycerides (TG) and BMI were significantly decreased in group (A), where the mean value of  Ad-
iponectin and High Density Lipoprotein Cholesterol (HDL-c) were significantly increased, while there were no significant 
changes in group (B). Also, there was a significant difference between both groups at the end of  the study. 
Conclusion: Weight loss modulates insulin resistance, adiponectin, leptin, inflammatory cytokine levels and markers of  
hepatic function in patients with nonalcoholic steatohepatitis.
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Non-alcoholic steatohepatitis (NASH) is a pathological 
condition characterized by accumulation of  lipids in the 
liver of  non-alcoholic individuals and consequent oxi-
dative stress leading to cirrhosis of  liver in the long run1. 
Incidence of  NASH in USA is 30% of  the adult popu-
lation2. Even, in Asian countries, number of  individuals 
being diagnosed with NASH is on the rise3. The clinical 
importance of  NASH is due to its potential to progress 
to liver cirrhosis, hepatocarcinoma and liver failure4. 
Non-alcoholic steatohepatitis is a growing public health 
problem with no approved therapy and projected to be 
the leading cause of  liver transplantation in the United 
States by 20205. 
Obese individuals are at maximum risk of  developing 
NASH6 and a strong positive correlation exists between 
insulin resistance (IR) and development of  NASH as 
obesity, non-insulin-dependent diabetes mellitus and 
hyperlipidaemia are the most common associations of  
the disease. Persons with central obesity are at particu-
lar risk7. The prevalence of  NASH is estimated to be as 
high as 40–100% in obese adults worldwide8.  
 
African Health Sciences Vol 16 Issue 1, March 2016242
Non alcoholic steatohepatitis is characterized by diffuse 
fatty acid infiltration and inflammation. The exact cause 
of  NASH is unclear, but it is increasingly becoming 
more evident that the disease is much more common 
than was previously thought4.  Inflammatory cytokines, 
IL-6, TNF-α and IL-8, and oxidative stress markers 
were significantly higher in the non-alcoholic steato-
hepatitis patients 9.
 
The pathogenesis of  NASH includes insulin resistance, 
increased inflammation, tumor necrosis factor-alpha 
(TNF-α), interleukin-6 (IL-6) and increased oxidative 
damage10-12. Moreover, leptin and adiponectin have 
been implicated in the pathogenesis of  both non-alco-
holic steatohepatitis and insulin resistance13. Tumor ne-
crosis factor-α and other TNF-induced cytokines such 
as interleukin-6 and interleukin-8 levels were higher in 
animals with NASH. This is likely related to the pro-
gression of  NASH in liver cirrhosis14. 
 
In many cases, NASH causes asymptomatic elevation 
of  plasma aspartate transaminase (AST) and alanine 
transaminase (ALT). However, ALT is most closely re-
lated to liver fat accumulation, and it has been used as an 
indicator of  NASH15. Moreover, insulin resistance plays 
a major role in the development of  NASH16.  However, 
serum concentrations of  tumor necrosis factor-alpha 
(TNF-α) are related to the severity of  insulin resistance 
and to central adiposity17.
 
The aim of  this study was to detect changes in biochem-
ical parameters including TNF-α, IL-6, IL-8, Leptin, 
Adiponectin, Insulin resistance, ALT, AST, TC, LDL-c, 
TG and HDL-c following weight loss in patients with 
nonalcoholic steatohepatitis.
Subjects, materials and methods
Subjects
One hundred obese nonalcoholic steatohepatitis pa-
tients of  both sexes (50 males & 50 females) were se-
lected from the Internal Medicine Department at King 
Abdul Aziz University Hospital and other Hospitals at 
Jeddah area. Their age was between 45-58 years, the 
body mass index (BMI) ranged from 30 to 35 Kg/m2. 
Subjects with a history of  smoking, cardiovascular dis-
ease, alcohol abuse problems, hepatic (i.e. infectious 
and viral disease) or renal disease were excluded from 
the study. Each patient underwent abdominal US (Sie-
mens Antares equipment with CH4-1 MHz transducer; 
Siemens Medical, Erlangen, Germany) in a fasting state. 
The presence of  hepatic steatosis was assessed inde-
pendently by radiologists according to findings such as 
hepatorenal contrast, blurring of  the vascular wall, and 
profound attenuation of  the diaphragm. According to 
the findings of  ultrasound examination patient group 
with NASH was divided into three; as minimal, mod-
erate and marked subgroup parallel to the increase in 
echogenicity18. The subjects were randomly allocated to 
the experimental group or control group. Each subject 
was given an envelope containing two cards and was 
instructed to blindly draw one card on each occasion. 
This study was single blinded: the person undertaking 
the assessment and data analysis was unaware of  the 
group of  each patient while the subjects and their ther-
apists were not blinded to the treatment group. Patients 
were included into 2 equal groups; the first group (A) 
received aerobic exercise training in addition to diet reg-
imen for 3 months, where the second group (B) received 
no treatment intervention.  The study was approved by 
the Ethics Committee of  King Abdulaziz University 
Hospital, Jeddah, Saudi Arabia and all patients signed 
informed consent for participation in this study.
Equipment
1) Treadmill (Track master 400E, gas fitness system, 
England) was used in performance of  walking exercise.
2) Commercial kits (Roche Diagnostics, Geneve, Swit-
zerland) were used to measure serum ALT, AST lev-
els; however commercial kits (Siemens Healthcare Di-
agnostics, Deerfield, USA) were used to measure IL-6, 
IL-8 and TNF-α level. Also, kits (Bioclin, Quibasa, Belo 
Horizonte, MG, Brazil) were used for measurements 
of  Homeostasis Model Assessment-Insulin Resistance 
(HOMA-IR) index for insulin sensitivity. Also, Com-
mercial kits (Randox, Tokyo, Japan) with K2EDTA 
were used to measure leptin, adiponectin, total choles-
terol, triacylglycerol, high-density lipoprotein cholester-
ol and low-density lipoprotein cholesterol. 
3) Weight and height scale (JENIX DS 102, Dongsang, 
South Korea) was used to measure weight and height to 
calculate the body mass index (BMI). Body mass index 
was calculated by dividing the weight in kilograms by 
the square of  the height in meters (Kg/m2). According 
to the WHO classification, a BMI of  <18.5 Kg/m2 is 
under weight, 18.5-24.9 Kg/m2 is normal 25-29.9 Kg/
m2 is overweight. A BMI of  > 30 Kg/m2 is classified as 
obese and this group was further divided into moderate 
obesity (30-34.9 Kg/m2), severe obesity (35-39.9 Kg/
m2) and very severe obesity (≥40 Kg/m2).
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Measurements
1. Laboratory analysis:
Venous blood samples were collected in polystyrene 
tubes after a 12-h fasting, by venipuncture of  the an-
tecubital vein while patients rested in a supine position. 
The blood samples were transported to a laboratory 
within 1 h and centrifuged at + 4 °C to remove serum 
(1000 = g for 10 min). Serum ALT, AST levels were 
assayed using a Cobas Integra 800 analyzer (Roche Di-
agnostics, Geneve, Switzerland). While IL-6 levels were 
measured using “Immulite 2000” immunassay analyz-
er (Siemens Healthcare Diagnostics, Deerfield, USA). 
However, interleukin-8 (IL-8) and TNF-α levels were 
analyzed with ELISA kits using ELISA microplate strip 
washer (ELX 50), and ELISA microplate reader (ELX 
808; BioTek Instruments, USA). Homeostasis Model 
Assessment-Insulin Resistance (HOMA-IR) index for 
insulin sensitivity was computed following this equa-
tion: fasting glycemia (mmol/L) x fasting insulin(mI-
U/L)/22.519 and was measured by the colorimetric 
enzymatic method using an automatic spectrophotom-
eter and respective kits for analysis (Bioclin, Quibasa, 
Belo Horizonte, MG, Brazil). Human insulin has been 
measured with an insulin kit (Roche Diagnostics, Indi-
anapolis, IN, USA) using a cobas immunoassay analyzer 
(Roche Diagnostics). Also, plasma sample with K2ED-
TA was collected after centrifugation (2000× g for 10 
min at 4°C) and stored at −80°C to analyze leptin, adi-
ponectin, total cholesterol, triacylglycerol, high-density 
lipoprotein cholesterol, low-density lipoprotein choles-
terol. All analyses were carried out on a Hitachi 7170 
Autoanalyser (Tokyo, Japan) or with commercial kits 
(Randox).
2. Evaluation of  anthropometric parameters
All measurements were performed at pre-treatment and 
after three months at the end of  the study. The patients 
were measured while wearing their undergarments and 
hospital gowns. Height was measured with a digital sta-
diometer to the nearest 0.1 cm (JENIX DS 102, Dong-
sang, South Korea). Body weight was measured on a 
calibrated balance scale to the nearest 0.1 kg (HC4211, 
Cas Korea, South Korea), and BMI was calculated as 
BMI = Body weight / (Height)2.
All measurements of  TNF-α, Il-6, IL-8, leptin, ad-
iponectin, HOMA-IR, ALT, AST, TC, LDL-c, TG, 
HDL-c and BMI were taken before the starting of  the 
study and after three months at the end of  the study.
Procedures
Following the previous evaluation, all patients were di-
vided randomly into the following groups:
1. The training group: Fifty nonalcoholic steatohep-
atitis patients of  both sexes received aerobic exercise 
training program and diet regimen. The aerobic tread-
mill-based training program (Track master 400E, gas 
fitness system, England) was at 65 % to 75 % of  the 
maximum heart rate (HRmax) achieved according to 
a modified Bruce protocol. After an initial, 5-minute 
warm-up phase performed on the treadmill at a low 
load, each endurance training session lasted 30 minutes 
and ended with 5-minute recovery and relaxation phase 
according to recommendation of  American College of  
Sports Medicine regarding the aerobic exercise applica-
tion20, three sessions / week (i.e. a total of  36 sessions 
over a 3-month period). Also, the interview-based food 
survey was performed by dieticians to specify previous 
food habits and possible anomalies in dietary behavior. 
The prescribed low calorie diet was balanced, with 15% 
as protein, 30 to 35% as fat and 50 to 55% as carbohy-
drate, on average, in order to provide about 1200 Kilo-
calories/day for three months21.
2. The control group:  Fifty non-alcoholic steatohepa-
titis patients of  both sexes were asked to maintain their 
ordinary current life style.
Statistical analysis
The mean values of  TNF-α, IL-6, IL-8, leptin, adiponec-
tin, HOMA-IR, ALT, AST, TC, LDL-c, TG, HDL-c 
and BMI obtained before and after three months in 
both groups were compared using paired "t" test. Inde-
pendent "t" test was used for the comparison between 
the two groups (P<0.05). Pearson’s product moment 
correlation coefficients (r) were applied to examine the 




One hundred NASH patients completed the screening 
evaluation and underwent randomization. The baseline 
characteristics of  the patients who underwent randomi-
zation are shown in Table (1). Most patients (70%) were 
men. Fifty patients were assigned to aerobic exercise 
and diet regimen (n = 50; 34 males and 16 females) and 
control group (n = 50, 36 males and 14 females). None 
of  the baseline characteristics differed significantly be-
tween the two groups as listed in table (1).
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Table (1): Mean value of demographic data and health state for patients in both groups. 
 
  Mean +SD P-value 
NASH Control  
Age (year) 50.78± 5.34 51.12± 5.86 0.098 
Gender ratio (male/female) 34/16 36/14 0.271 
Weight (kg) 93.24 ± 6.51 92.85± 6.22 0.152 
Height (cm) 173.11± 7.82 172.35 ± 6.95 0.084 
BMI (kg/m2) 32.35± 2.54 31.76± 2.92 0.093 
Waist–hip ratio 0.97± 0.15 0.96 ± 0.06 0.125 
Systolic BP, mm Hg 141.26± 12.56 140.87 ± 11.93 0.157 
Diastolic BP, mm Hg 89.31 ±8.64 88.75 ± 10.21 0.162 
HbA1C, % 5.28 ± 0.96 5.6 ± 0.84 0.063 
Bilirubin level, mol/L 13.83 ± 3.41 14.25 ± 4.3 0.921 
Albumin level, g/L 43.57± 2.73 42.78 ± 3.11 0.073 
        BMI: Body mass index; BP: Blood pressure; HBA1c: Glcocylated hemoglobin 
Further, a significant decrease (P < 0.05) in the anthro-
pometric measurements including BMI was observed 
with the lifestyle intervention group of  NASH pa-
tients who received dietary and exercise therapy  for 3 
months, compared to NASH patients of  control group 
(see Table 2). 
Table (2): Mean value and significance of BMI, TNF-α, IL-6, IL-8, ALT, AST,TC,LDL-c, HDL-
c, TG, HOMA-IR in group (A) before and after treatment. 
  
  Mean +SD P-value 
Before After 
BMI (kg/m2) 32.35± 2.54 29.15± 2.48* 0.0035 
TNF- α (pg/mL) 12.76 ± 2.21 8.21 ± 2.35* 0.0083 
IL-6 (pg/mL) 5.26 ± 1.52 3.40 ± 1.17* 0.0077 
IL-8 (pg/mL) 18.53 ± 3.78 15.16 ± 3.35* 0.0056 
Leptin    Ng/ml 41.64 ± 5.24 36.68 ±4.76* 0.0043 
Adiponectin (μg/mL) 10.51 ± 3.73 14.96 ± 3.54* 0.0034 
ALT (U/L) 46.32 ± 4.65 34.65± 4.13* 0.0035 
AST (U/L) 44.71 ± 5.53 35.22± 4.97* 0.0023 
TC  (mg/dl) 196.11±12.42 171.63 ±11.04* 0.0019 
LDL-c  (mg/dl) 136.52 ±10.84 118.31  ± 11.15* 0.0024 
TG   (mg/dl) 157.14 ±11.06 124.17 ±10.43* 0.0018 
HDL-c  (mg/dl) 34.65 ±2.87 38.11 ±2.32* 0.0037 
HOMA-IR 4.92 ± 2.36 2.95 ± 1.98* 0.0026 
BMI: Body mass index; TNF-α: tumor necrosis factor – alpha; IL-6: Interleukin-6; IL-8: Interleukin-8; ALT: 
Alanine aminotransferase; AST: Aspartate aminotransferase; TC:  Total cholesterol; LDL-c: Low density 
lipoprotein cholesterol; HDL-c: High density lipoprotein cholesterol; TG: Triglyceride; HOMA-IR: 
Homeostasis Model Assessment-Insulin Resistance Index;* Significant level (p<0.05). 
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While at the same time, HDL-C level was somewhat 
reduced among the control group of  NASH patients. 
On the other hand, the LDL-C level decreased among 
lifestyle intervention group, whereas an increasing trend 
was observed for the control group of  NASH patients, 
as LDL-C considered to be bad cholesterol with  levels 
of  less than 130 normally recommended. The TC of  
lifestyle intervention group could be maintained very 
close to its recommended level of  200 throughout the 
treatment duration, while TC was found to be slight-
ly increased among the control NASH patients which 
might indicate a potential risk for atherosclerosis de-
velopment by accumulation of  cells containing excess 
lipids within the arterial wall that are closely related to 
NASH development(see Table 2 and 3).
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Table (4): Table (2): Mean value and significance of BMI, TNF-α, IL-6, IL-8, ALT, 
AST,TC,LDL-c, HDL-c, TG, HOMA-IR in group (A) and group (B) after the study. 
 
  Mean +SD P-value 
Group (A) Group (B) 
BMI (kg/m2) 29.15± 2.48* 31.98± 2.87 0.0046 
TNF- α (pg/mL) 8.21 ± 2.35* 13.54 ± 2.56 0.0091 
IL-6 (pg/mL) 3.40 ± 1.17* 5.98 ± 1.95 0.0083 
IL-8 (pg/mL) 15.16 ± 3.35* 19.23 ± 3.57 0.0057 
Leptin    Ng/ml 36.68 ±4.76* 42.11± 4.92 0.0052 
Adiponectin (μg/mL) 14.96 ± 3.54* 10.85 ± 2.97 0.0038 
ALT (U/L) 34.65± 4.13* 46.94 ± 4.62 0.0044 
AST (U/L) 35.22± 4.97* 45.17 ± 5.21 0.0038 
TC  (mg/dl) 171.63 ±11.04* 196.85±10.88 0.0026 
LDL-c  (mg/dl) 118.31  ± 11.15* 137.92 ±10.73 0.0029 
TG   (mg/dl) 124.17 ±10.43* 159.26 ±11.17 0.0022 
HDL-c  (mg/dl) 38.11 ±2.32* 34.85 ±2.62 0.0051 
HOMA-IR 2.95 ± 1.98* 4.75 ± 2.15 0.0063 
      BMI: Body mass index; TNF-α: tumor necrosis factor – alpha; IL-6: Interleukin-6;IL-8: Interleukin-8; ALT:  
      Alanine aminotransferase; AST: Aspartate aminotransferase; TC:  Total cholesterol; LDL-c: Low density  
      lipoprotein cholesterol; HDL-c: High density lipoprotein cholesterol; TG: Triglyceride; HOMA-IR: 
Homeostasis  
      Model Assessment-Insulin Resistance Index;* Significant level (p<0.05). 
Table (3): Mean value and significance of BMI, TNF-α,IL-6, IL-8, ALT, AST,TC,LDL-c, HDL-
c, TG, HOMA-IR in group (B) before and after the study. 
  
  Mean +SD P-value 
Before After 
BMI (kg/m2) 31.76± 2.92 31.98± 2.87 0.126 
TNF- α (pg/mL) 12.98 ± 2.37 13.54 ± 2.56 0.114 
IL-6 (pg/mL) 5.76 ± 1.71 5.98 ± 1.95 0.137 
IL-8 (pg/mL) 18.85 ± 3.26 19.23 ± 3.57 0.210 
Leptin    Ng/ml 41.57 ± 5.13 42.11± 4.92 0.251 
Adiponectin (μg/mL) 10.36 ± 3.15 10.85 ± 2.97 0.134 
ALT (U/L) 46.53 ± 4.27 46.94 ± 4.62 0.116 
AST (U/L) 44.80 ± 5.53 45.17 ± 5.21 0.131 
TC  (mg/dl) 195.83±11.54 196.85±10.88 0.315 
LDL-c  (mg/dl) 137.11 ±10.16 137.92 ±10.73 0.271 
TG   (mg/dl) 158.45 ±11.32 159.26 ±11.17 0.127 
HDL-c  (mg/dl) 35.21 ±2.33 34.85 ±2.62 0.113 
HOMA-IR 4.48 ± 2.17 4.75 ± 2.15 0.254 
BMI: Body mass index; TNF-α: tumor necrosis factor – alpha; IL-6: Interleukin-6; IL-8: Interleukin-8; ALT: 
Alanine aminotransferase; AST: Aspartate aminotransferase; TC:  Total cholesterol; LDL-c: Low density 
lipoprotein cholesterol; HDL-c: High density lipoprotein cholesterol; TG: Triglyceride; HOMA-IR: 
Homeostasis Model Assessment-Insulin Resistance Index. 
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Considerable changes were observed in the serum lipid 
profiles of  the NASH patients within the lifestyle inter-
vention group of  NASH patients; the results are shown 
in Table 4. The concentration of  TG in the blood that 
usually provides energy for different metabolic process-
es was effectively controlled among the lifestyle inter-
vention group, whereas the TG level was higher for the 
control group even after 3 months of  dietary and exer-
cise therapy. An increase in HDL-C level was observed 
in lifestyle intervention group, which is a good indicator 
of  the improvement in NASH patients because its high 
level seems to be associated with low incidence of  cor-
onary heart diseases. 
BMI: Body mass index; TNF-α: tumor necrosis factor – alpha; IL-6: Interleukin-6;IL-8: Interleukin-8; 
ALT: Alanine amino transferase; AST: Aspartate amino transferase; TC:  Total cholesterol; LDL-c: 
Low density lipoprotein cholesterol; HDL-c: High density lipoprotein cholesterol; TG: Triglyceride; 
HOMA-IR: Homeostasis Model Assessment-Insulin Resistance Index;* Significant level (p<0.05).
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In the lifestyle intervention group of  NASH patients, 
the values of  leptin, TNF- α, IL6, IL8 and HOMA-IR 
were considerably reduced to significant levels over the 
period of  therapy. While, the levels of  these parameters 
were continuously increased in the control group of  
NASH patients. Also, as is evident from Tables 2, 3 and 
4, the lifestyle intervention group of  NASH patients 
had significant change in levels of  AST and ALT from 
baseline, however ; there was a progressive rise in AST 
and ALT levels for the control group NASH patients. 
Moreover, there was a positive relationship between 
weight changes and levels of   AST and ALT in both 
groups( Tables 5 and 6).
Table (5): The Pearson’s correlation coefficients test values and the relationship between 
the BMI, ALT, AST in group (A). 
 
Test Pearson’s value Test Pearson’s value Relationship to body mass index 
Alanine aminotransferase  0.82 Strong direct relationship 
Aspartate 
aminotransferase   0.81 Strong direct relationship 





Table (6): The Pearson’s correlation coefficients test values and the relationship between 
theBMI, ALT, AST in group (B). 
  
Test Pearson’s value Test Pearson’s value Relationship to body mass index 
Alanine aminotransferase  0.83 Strong direct relationship 
Aspartate 
aminotransferase   0.80 Strong direct relationship 
     BMI : Body mass index ;  ALT :Alanineaminotransferase ; AST : Aspartate aminotransferase   
 
Discussion
The aim of  this study was to detect changes in bio-
chemical parameters following weight loss in patients 
with non-alcoholic steatohepatitis.  The mean values of  
leptin, TNF- α, IL6, IL8, ALT, AST, HOMA-IR, TC, 
LDL-c, TG and BMI were significantly decreased in 
group (A), where the mean value of  adiponectin and 
HDL-c were significantly increased, while there were 
no significant changes in group (B). Also; there was a 
significant difference between both groups at the end 
of  the study, these findings are supported and agreed 
by several previous studies.
 
There is a growing concern for NASH as the next big 
therapeutic challenge in hepatology because of  the pos-
sible evolution of  NASH toward end-stage liver dis-
ease, as well as the need for liver transplantation. The 
novel of  this study is that although exercise and diet im-
provement may reduce the overall magnanimity of  in-
sulin resistance, hyperlipidemia and abnormal cytokine 
metabolism, there has been only limited research on the 
effects of  weight reduction as the sole intervention on 
these abnormal biochemical parameters in individuals 
with NASH. However, the limitation of  this study is no 
recording of  the histological changes to the treatment 
intervention 
 
Results of  our study was confirmed with Dandona et 
al. who reported that weight loss reduces TNF- α in 
the obese22. Also, Sandoval and Davis approved that 
patients who had bariatric surgery gained reduction in 
IL-6 concentration and improved insulin sensitivity in 
parallel to weight loss23. However, Chu  and colleagues 
confirmed that serum leptin level was reduced after 
weight reduction program24.  Also, Arita and co-authors 
found that exercise training resulted in both reduction 
in serum leptin and improved leptin sensitivity25. Ruche 
and McDonald confirmed that weight loss induces adi-
ponectin synthesis26.
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Ueno and colleagues conducted their study of  weight 
reducing program on thirty-five obese NIDDM pa-
tients for twelve weeks (diet restriction and exercise) 
and confirmed that improved serum leptin, lipopro-
tein profile, insulin sensitivity and glucose control were 
associated with weight loss27. Tilg and Kaser  in their 
previous study on twenty-five obese patients with fatty 
liver on three months of  restricted diet and exercise, 
concluded that weight reduction was associated with re-
duction in serum levels of  aminotransferase, albumin, 
total cholesterol and fasting blood glucose28.  
Conclusion
Weight loss modulates insulin resistance, adiponectin, 
leptin, inflammatory cytokines and markers of  hepatic 
function in patients with non-alcoholic steatohepatitis.
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